CL2014003560A1 - Compuestos y su uso terapeutico - Google Patents
Compuestos y su uso terapeuticoInfo
- Publication number
- CL2014003560A1 CL2014003560A1 CL2014003560A CL2014003560A CL2014003560A1 CL 2014003560 A1 CL2014003560 A1 CL 2014003560A1 CL 2014003560 A CL2014003560 A CL 2014003560A CL 2014003560 A CL2014003560 A CL 2014003560A CL 2014003560 A1 CL2014003560 A1 CL 2014003560A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- therapeutic use
- cancer
- bifenil
- iloxi
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 abstract 1
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPUESTOS DERIVADOS DE {[({(BIFENIL-2-ILOXI)FENIL}CARBAMOIL)AMINO]METIL}PIRIDINIO, INHIBIDORES DE Nampt; METODO DE PREPARACION; COMPOSICION FARMACEUTICA; METODO DE DETECCION DE CANCER; Y SU USO PARA EL TRATAMIENTO DEL CANCER, INFLAMACION SISTEMICA O CRONICA, ARTRITIS REUMATOIDE, DIABETES, OBESIDAD, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665297P | 2012-06-27 | 2012-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003560A1 true CL2014003560A1 (es) | 2015-11-27 |
Family
ID=49783870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003560A CL2014003560A1 (es) | 2012-06-27 | 2014-12-29 | Compuestos y su uso terapeutico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150344426A1 (es) |
| EP (1) | EP2867209A4 (es) |
| JP (1) | JP2015522028A (es) |
| KR (1) | KR20150024932A (es) |
| CN (1) | CN104768931A (es) |
| AU (1) | AU2013284487A1 (es) |
| BR (1) | BR112014032917A2 (es) |
| CL (1) | CL2014003560A1 (es) |
| IL (1) | IL236499A0 (es) |
| IN (1) | IN2015KN00240A (es) |
| MA (1) | MA37808A1 (es) |
| MX (1) | MX2015000101A (es) |
| PH (1) | PH12015500179A1 (es) |
| RU (1) | RU2015102278A (es) |
| SG (1) | SG11201408770RA (es) |
| WO (1) | WO2014004884A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6510556B2 (ja) | 2014-04-18 | 2019-05-08 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キノキサリン化合物及びその使用 |
| WO2015176135A1 (en) * | 2014-05-22 | 2015-11-26 | The University Of Sydney | Omega-3 analogues |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| ES2742197T7 (es) * | 2015-07-23 | 2021-10-06 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| FR3047552A1 (fr) * | 2016-02-05 | 2017-08-11 | Air Liquide | Introduction optimisee d'un courant refrigerant mixte diphasique dans un procede de liquefaction de gaz naturel |
| JPWO2017170826A1 (ja) * | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−１受容体作用増強活性を有する化合物 |
| KR101869794B1 (ko) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| WO2018067702A1 (en) | 2016-10-04 | 2018-04-12 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
| CN111263758A (zh) | 2017-06-30 | 2020-06-09 | 麻省理工学院 | 支链的多官能大分子单体和相关聚合物及其用途 |
| WO2019006425A1 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | IMAGING AGENTS OF BRUSH ARRAY STAR POLYMERS AND USES THEREOF |
| CA3129412A1 (en) | 2018-04-13 | 2019-10-17 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| KR101937126B1 (ko) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| CA3117152A1 (en) * | 2018-10-22 | 2020-04-30 | Yale University | Identification of ppm1d mutations as a novel biomarker for nampti sensitivity |
| US12478683B2 (en) | 2019-10-16 | 2025-11-25 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| US12042513B2 (en) | 2020-01-10 | 2024-07-23 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof |
| WO2023121753A1 (en) | 2021-12-20 | 2023-06-29 | Massachusetts Institute Of Technology | Biomolecule-polymer-pharmaceutical agent conjugates for delivering the pharmaceutical agent |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
| BR0309996A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| US8871747B2 (en) * | 2008-08-29 | 2014-10-28 | Topotarget A/S | Urea and thiourea derivatives |
| BR112012021806A2 (pt) * | 2010-03-01 | 2015-09-08 | Myrexis Inc | compostos e seus usos terapêusticos. |
| RU2617424C2 (ru) * | 2010-09-03 | 2017-04-25 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
-
2013
- 2013-06-27 CN CN201380045302.4A patent/CN104768931A/zh active Pending
- 2013-06-27 KR KR20157002268A patent/KR20150024932A/ko not_active Withdrawn
- 2013-06-27 RU RU2015102278A patent/RU2015102278A/ru not_active Application Discontinuation
- 2013-06-27 JP JP2015520521A patent/JP2015522028A/ja active Pending
- 2013-06-27 EP EP13810056.5A patent/EP2867209A4/en not_active Withdrawn
- 2013-06-27 IN IN240KON2015 patent/IN2015KN00240A/en unknown
- 2013-06-27 MA MA37808A patent/MA37808A1/fr unknown
- 2013-06-27 WO PCT/US2013/048274 patent/WO2014004884A1/en not_active Ceased
- 2013-06-27 MX MX2015000101A patent/MX2015000101A/es unknown
- 2013-06-27 SG SG11201408770RA patent/SG11201408770RA/en unknown
- 2013-06-27 AU AU2013284487A patent/AU2013284487A1/en not_active Abandoned
- 2013-06-27 BR BR112014032917A patent/BR112014032917A2/pt not_active IP Right Cessation
-
2014
- 2014-12-24 US US14/582,641 patent/US20150344426A1/en not_active Abandoned
- 2014-12-28 IL IL236499A patent/IL236499A0/en unknown
- 2014-12-29 CL CL2014003560A patent/CL2014003560A1/es unknown
-
2015
- 2015-01-27 PH PH12015500179A patent/PH12015500179A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA37808A1 (fr) | 2018-03-30 |
| SG11201408770RA (en) | 2015-01-29 |
| EP2867209A4 (en) | 2015-11-25 |
| BR112014032917A2 (pt) | 2017-06-27 |
| US20150344426A1 (en) | 2015-12-03 |
| PH12015500179A1 (en) | 2015-04-06 |
| KR20150024932A (ko) | 2015-03-09 |
| MX2015000101A (es) | 2015-06-22 |
| IL236499A0 (en) | 2015-02-26 |
| CN104768931A (zh) | 2015-07-08 |
| AU2013284487A1 (en) | 2015-02-19 |
| JP2015522028A (ja) | 2015-08-03 |
| WO2014004884A1 (en) | 2014-01-03 |
| RU2015102278A (ru) | 2016-08-20 |
| EP2867209A1 (en) | 2015-05-06 |
| IN2015KN00240A (es) | 2015-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014003560A1 (es) | Compuestos y su uso terapeutico | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| CL2016000866A1 (es) | Forma salina de hidrocloruro para la inhibición de ezh2 | |
| MX376008B (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
| BR112014015003A2 (pt) | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2011002943A1 (es) | Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica. | |
| CL2015001392A1 (es) | Compuestos y sus métodos de empleo | |
| EA201391285A1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
| MX376329B (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2015003315A1 (es) | Inhibidores de acc y usos de los mismos | |
| CL2014000032A1 (es) | Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros | |
| MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
| PL2729151T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| BR112014005091A2 (pt) | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ |